The BM rate may then be even higher in molecularly selected groups, such as epidermal growth factor receptor (EGFR) mutated or anaplastic lymphoma kinase (ALK) positive NSCLC patients (8). This evidence concerns the gene EGFR and non-small cell lung carcinoma.